Skip to content
New: 100+ more US companies, including the big banks, plus insider trades from SEC filings

Compare · Health Care

Bristol Myers Squibb vs. Pfizer: how they make money

The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

How they differ

In FY2025, Pfizer's revenue of $62.6B was about 1.3 times Bristol Myers Squibb's $48.2B (Cityfort calculation: one divided by the other).

Bristol Myers Squibb's largest segment is Growth Portfolio, 54.8% of revenue in FY2025; Pfizer's largest segment is Primary Care, 42.9% of revenue in FY2025.

United States brought in 69.1% of Bristol Myers Squibb's revenue in FY2025; United States brought in 59.2% of Pfizer's revenue in FY2025.

Bristol Myers Squibb's largest payer group is Customers in the US, 69.1% of revenue (FY2025); Pfizer's largest payer group is Customers in the US, 59.2% of revenue (FY2025).

Neither page lists the other among its competitors.

Sources: Bristol Myers Squibb S1 · Pfizer S1, S6

Each company in 5 points

Bristol Myers Squibb

  1. 1 · What it sells

    Bristol Myers Squibb sells prescription medicines, and the blood thinner Eliquis brought in $14.4 billion and the cancer medicine Opdivo $10.0 billion of its $48.2 billion of FY2025 revenue.

    Sources and detail on the Bristol Myers Squibb page
  2. 2 · Who pays it

    BMS reports no net revenue by customer or final payer; by location, in FY2025 US customers paid 69.1% of revenue, customers elsewhere 28.7% and partners and royalty payers 2.3%.

    Sources and detail on the Bristol Myers Squibb page
  3. 3 · What it keeps from $100

    Of every $100 of FY2025 revenue, BMS kept $14.6 as net income after $7.7 of charges for bought research, and operating income, a Cityfort calculation from the FY2025 10-K, was $20.8.

    Sources and detail on the Bristol Myers Squibb page
  4. 4 · Where the operating profit comes from

    BMS reports one segment and no profit by product, so profit comes from the whole portfolio, where the Growth Portfolio of newer medicines was 54.8% of FY2025 revenue.

    Sources and detail on the Bristol Myers Squibb page
  5. 5 · The one thing to watch

    Eliquis and Opdivo were 30.0% and 20.9% of BMS's FY2025 revenue, and BMS estimates US exclusivity for both ends in 2028.

    Sources and detail on the Bristol Myers Squibb page

Pfizer

  1. 1 · What it sells

    Pfizer sells medicines and vaccines worldwide, and 12 products of more than $1 billion each were 65% of its $62.6 billion of FY2025 revenue.

    Sources and detail on the Pfizer page
  2. 2 · Who pays it

    Pfizer reports no revenue by final payer and three US wholesalers bought 54 percent; by location, in FY2025 the US paid 59.2% of revenue, other developed markets 25.9% and emerging markets 14.9%.

    Sources and detail on the Pfizer page
  3. 3 · What it keeps from $100

    Of every $100 of FY2025 revenue, Pfizer kept $12.4 as net income, after $10.7 of other deductions that included $7.8 of impairment charges, and with a $0.4 tax benefit; operating income, a Cityfort calculation from the FY2025 10-K, was $22.8.

    Sources and detail on the Pfizer page
  4. 4 · Where the operating profit comes from

    Biopharma, Pfizer's one reportable segment, earned $29.3 billion in FY2025 before amortization and other items, other activities lost $8.2 billion, and Pfizer gives no earnings by product group.

    Sources and detail on the Pfizer page
  5. 5 · The one thing to watch

    Settled generic companies may launch Eliquis, Pfizer's largest product at $8.0 billion of FY2025 revenue, in the US from Apr 1, 2028, and Pfizer said on Nov 3, 2026 that it expects generic and biosimilar competition to cost about $1.1 billion of 2026 revenue.

    Sources and detail on the Pfizer page

Where each $100 went

Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.

Bristol Myers Squibb

Where $100 went · FY2025

Where $100 of Bristol Myers Squibb's money went in FY2025
Research and development$20.6
Cost of products sold$28.9
Selling, general and administrative$15.1
Acquired research (Acquired IPRD)$7.7
Amortization of acquired intangibles$6.9
Income tax and other expense$6.1
Kept as net income$14.6
Total$100

Cityfort calculation from the FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $48.2 billion × 100. Other items were a net cost, so no other income is added. Lines are rounded.

Pfizer

Where $100 went · FY2025

Where $100 of Pfizer's money went in FY2025
Research and development$16.7
Cost of making products$25.7
Selling, informational and admin$22.0
Other deductions (impairments, interest, legal)$10.7
Amortization of bought rights$7.8
Research bought from others (acquired IPR&D)$2.6
Restructuring and deal costs$2.5
Tax benefit and small items (adds)−$0.4
Kept as net income$12.4
Total$100

Cityfort calculation from the FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $62.6 billion × 100. Net other items were a cost, so no other income is added. Other deductions include $7.8 of intangible asset impairments ($4.9 billion). The tax line is a benefit, so it adds $0.4.

Line items differ because each company groups its costs its own way in its filings. Only on Bristol Myers Squibb's receipt: Cost of products sold; Selling, general and administrative; Acquired research (Acquired IPRD); Amortization of acquired intangibles; Income tax and other expense. Only on Pfizer's receipt: Cost of making products; Selling, informational and admin; Other deductions (impairments, interest, legal); Amortization of bought rights; Research bought from others (acquired IPR&D); Restructuring and deal costs; Tax benefit and small items (adds).

Sources: Bristol Myers Squibb S1 · Pfizer S1

Revenue, net income and free cash flow

Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).

Revenue

Bristol Myers Squibb

Pfizer

Both charts use the same scale. Each company's own fiscal years.
See the numbers
Revenue of Bristol Myers Squibb and Pfizer by fiscal year, US$
Bristol Myers Squibb yearBristol Myers Squibb revenuePfizer yearPfizer revenue
FY2021$46.4BFY2021$81.3B
FY2022$46.2BFY2022$101.2B
FY2023$45.0BFY2023$59.6B
FY2024$48.3BFY2024$63.6B
FY2025$48.2BFY2025$62.6B

Net income

Bristol Myers Squibb

Pfizer

Both charts use the same scale. Each company's own fiscal years.
See the numbers
Net income of Bristol Myers Squibb and Pfizer by fiscal year, US$
Bristol Myers Squibb yearBristol Myers Squibb net incomePfizer yearPfizer net income
FY2021$7.0BFY2021$22.0B
FY2022$6.3BFY2022$31.4B
FY2023$8.0BFY2023$2.1B
FY2024−$8.9BFY2024$8.0B
FY2025$7.1BFY2025$7.8B

Free cash flow

Bristol Myers Squibb

Pfizer

Both charts use the same scale. Each company's own fiscal years; free cash flow = cash from operations minus capital spending, as on each company's page.
See the numbers
Free cash flow of Bristol Myers Squibb and Pfizer by fiscal year, US$
Bristol Myers Squibb yearBristol Myers Squibb free cash flowPfizer yearPfizer free cash flow
FY2021$15.2BFY2021$29.9B
FY2022$11.9BFY2022$26.0B
FY2023$12.7BFY2023$4.8B
FY2024$13.9BFY2024$9.8B
FY2025$12.8BFY2025$9.1B

Sources: Bristol Myers Squibb S3, S4, S1, S2 · Pfizer S3, S2, S1

Growth and net margin, FY2021 to FY2025

Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.

Bristol Myers Squibb

Revenue, per year
+1.0%
Net income, per year
+0.2%

Pfizer

Revenue, per year
−6.3%
Net income, per year
−22.9%

Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.

Net margin by year
Net margin (net income as a share of revenue) of Bristol Myers Squibb and Pfizer by fiscal year, as on each page
YearBristol Myers SquibbPfizer
FY202115.1%27.0%
FY202213.7%31.0%
FY202317.8%3.6%
FY2024−18.5%12.6%
FY202514.6%12.4%

Sources: Bristol Myers Squibb S3, S4, S1, S2 · Pfizer S3, S2, S1

Latest quarter, against the same quarter a year earlier

Each page's latest quarter as reported; the change is a Cityfort calculation.

Bristol Myers Squibb

Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025

Bristol Myers Squibb, Q3 FY2026 against Q3 FY2025
MeasureQ3 FY2026Q3 FY2025Change
Revenue$13.1B$12.2B+6.9%
Net income$2.2B$2.2B−1.8%

Pfizer

Q3 FY2026, the quarter to Sep 27, 2026, against Q3 FY2025

Pfizer, Q3 FY2026 against Q3 FY2025
MeasureQ3 FY2026Q3 FY2025Change
Revenue$16.6B$16.7B−0.4%
Net income$3.2B$3.5B−8.4%

Sources: Bristol Myers Squibb S15, S8, S14, S1, S13, S7, S12, S6, S11, S5 · Pfizer S16, S9, S15, S1, S14, S8, S13, S7, S12, S6

Who pays each company

Bristol Myers Squibb

  • Customers in the US · 69.1% of revenue69.1% of FY2025 revenue ($33.3 billion). Most US sales go through three wholesalers. Shares here are by location, because BMS does not report net revenue by customer or final payer.
  • Customers outside the US · 28.7% of revenue28.7% of FY2025 revenue ($13.8 billion).
  • Partners and royalty payers · 2.3% of revenue2.3% of FY2025 revenue ($1.1 billion): alliance and royalty revenue that BMS does not assign to a region.

Pfizer

  • Customers in the US · 59.2% of revenue59.2% of FY2025 revenue ($37.1 billion). Most US sales go through wholesalers, while Medicare, Medicaid and contract payers take rebates. Shares here are by location, because Pfizer does not report revenue by final payer.
  • Customers in other developed markets · 25.9% of revenue25.9% of FY2025 revenue ($16.2 billion).
  • Customers in emerging markets · 14.9% of revenue14.9% of FY2025 revenue ($9.3 billion). China, the largest country outside the US, was 5% of total revenue.

Sources: Bristol Myers Squibb S1 · Pfizer S1

Revenue by segment

Bristol Myers Squibb

FY2025

Bristol Myers Squibb revenue by segment, FY2025
SegmentRevenueShare
Growth Portfolio$26.4B54.8%
Legacy Portfolio$21.8B45.2%

Pfizer

FY2025

Pfizer revenue by segment, FY2025
SegmentRevenueShare
Primary Care$26.8B42.9%
Specialty Care$17.5B28.0%
Oncology$16.8B26.9%
Other business activities$1.4B2.2%

Sources: Bristol Myers Squibb S1 · Pfizer S1, S6

Where the revenue comes from

Revenue by region, as each company splits it, with the period.

Bristol Myers Squibb

FY2025

  • United States69.1%
  • International28.7%
  • Other (alliance and royalty revenue not assigned to a region)2.3%

Pfizer

FY2025

  • United States59.2%
  • Other developed markets25.9%
  • Emerging markets14.9%

Sources: Bristol Myers Squibb S1 · Pfizer S1

Debt and cash

Bristol Myers Squibb

Debt
$42.9B
Cash and investments
$13.0B

On Sep 30, 2026.

At Sep 30, 2026 BMS's debt exceeded its cash and marketable debt securities by $29.9 billion, as stated in the Q3 FY2026 10-Q, down from $38.5 billion at Dec 31, 2024. That is about 2.8 times operating cash flow over the last four quarters (Cityfort calculation from the FY2025 10-K, Q3 FY2025 10-Q and Q3 FY2026 10-Q).

Pfizer

Debt
$62.7B
Cash and investments
$14.3B

On Sep 27, 2026.

At Sep 27, 2026 Pfizer's debt exceeded its cash and short-term investments by $48.4 billion, down from $51.2 billion at Dec 31, 2025. That is about 3.4 times operating cash flow over the last four quarters (Cityfort calculation from the FY2025 10-K, Q3 FY2025 10-Q and Q3 FY2026 10-Q).

Sources: Bristol Myers Squibb S5, S1, S2, S8 · Pfizer S6, S1, S9, S3, S4

Who owns each company

Bristol Myers Squibb

  • One class of shares.
  • Officers and directors as a group: 0.1% of shares (as of Mar 12, 2026).
  • Vanguard Capital Management: 7.5% (as of Apr 29, 2026).
  • BlackRock, Inc.: 7.1% (as of Apr 17, 2025).
  • State Street Corporation: 5.0% (as of Aug 7, 2026).
  • 2 more holders on the Bristol Myers Squibb page.

Pfizer

  • One class of shares.
  • Officers and directors as a group: 0.0% of shares (as of Jan 31, 2026).
  • BlackRock, Inc.: 7.7% (as of Jan 26, 2024).
  • Vanguard Capital Management: 7.5% (as of May 1, 2026).
  • State Street Corporation: 5.1% (as of Jan 29, 2024).
  • 1 more holders on the Pfizer page.

Sources: Bristol Myers Squibb S19, S5, S21, S23, S20 · Pfizer S20, S1, S6, S21

What protects each business

What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.

Bristol Myers Squibb

  • Patents on the main medicines

    BMS estimates US exclusivity for Eliquis and Opdivo to 2028, Reblozyl to 2031, Breyanzi to 2033 and Camzyos to 2036. Revlimid and Pomalyst already face US generics.

  • Research spending

    BMS spent $10.0 billion on research and development in FY2025, 20.6% of revenue, plus $3.7 billion on acquired research.

  • Newer products

    The Growth Portfolio rose from $16.8 billion in FY2022 to $26.4 billion in FY2025, 54.8% of revenue.

  • Pricing power

    A Medicare set price applies to Eliquis from Jan 1, 2026 and to Pomalyst from Jan 1, 2027. Under a December 2025 agreement with the US government, Eliquis is free to Medicaid from Jan 1, 2026.

Pfizer

  • Range of products

    Twelve products each brought in more than $1 billion in FY2025 and were 65% of revenue. The largest, Eliquis, was 13%.

  • Research spending

    Pfizer spent $10.4 billion on research and development in FY2025, 16.7% of revenue, plus $1.6 billion on acquired research.

  • Global reach

    Revenue exceeded $500 million in each of 12 countries outside the US in 2025, and 40.8% of FY2025 revenue came from outside the US.

  • Patents on the main medicines

    Basic US patents on Padcev and Lorbrena run to 2033 and Prevnar 20 to 2035. Those on Ibrance and Xtandi run to 2027, and settled generic companies may launch Eliquis from Apr 1, 2028.

  • Pricing power

    Medicare set a negotiated Eliquis price from Jan 1, 2026, with Ibrance and Xtandi following in 2027. Pfizer also agreed with the US government to make certain prices more comparable to other developed countries.

Sources: Bristol Myers Squibb S1, S5, S2 · Pfizer S1, S6, S32

Where growth could come from

Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.

Bristol Myers Squibb

  • Eliquis · Working: on track against what the company said$4.7B in Q3 FY2026, up 25%
  • Opdivo and Opdivo Qvantig · Mixed: partly on track$2.7B in Q3 FY2026
  • Breyanzi · Working: on track against what the company said$526M in Q3 FY2026, up 46%
  • Camzyos · Working: on track against what the company said$420M in Q3 FY2026, up 42%
  • Reblozyl · Working: on track against what the company said$750M in Q3 FY2026, up 22%
  • Cobenfy (from Karuna) · Early: too early to judge$57M in Q3 FY2026
  • Zenbexus and other new approvals · New: recently announcedFDA approval on Aug 13, 2026

Pfizer

  • Eliquis · Mixed: partly on track$2.5B in Q3 FY2026, up 25%
  • Vyndaqel family · Working: on track against what the company said$1.8B in Q3 FY2026, up 11%
  • Padcev · Working: on track against what the company said$720M in Q3 FY2026, up 55%
  • Nurtec · Working: on track against what the company said$547M in Q3 FY2026, up 33%
  • Obesity programs from Metsera · Early: too early to judge10 Phase 3 studies planned in 2026
  • Licensed-in cancer programs · New: recently announced$650M paid to Innovent in 2026
  • Cost programs · Working: on track against what the company said$5.1B saved through 2025

Sources: Bristol Myers Squibb S5, S11, S1, S15, S3, S12, S2 · Pfizer S12, S6, S1, S13, S3, S4, S27

Dividends, buybacks, auditor and credit rating

Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.

Bristol Myers Squibb

  • Dividends per shareFY2021: $2.01 (62.9% of profit) · FY2022: $2.19 (73.2% of profit) · FY2023: $2.31 (59.1% of profit) · FY2024: $2.42 · FY2025: $2.49 (71.5% of profit)
  • Buybacks
    • Dec 31, 2022: Bought back $8.0 billion of its own shares in 2022. ($8.0B)
    • Dec 31, 2023: Bought back $5.2 billion of its own shares in 2023. BMS bought none in 2024, 2025 or the first nine months of 2026, and $5.0 billion of its authorization remained at Dec 31, 2025. ($5.2B)
  • AuditorDeloitte & Touche LLP, since 2006
  • Credit ratingMoody's and S&P (as stated in BMS's FY2025 10-K): A2 (Moody's) and A (S&P); short-term Prime-1 and A-1, outlook Stable (Feb 11, 2026)

Pfizer

  • Dividends per shareFY2021: $1.57 (39.7% of profit) · FY2022: $1.61 (28.6% of profit) · FY2023: $1.65 (436.4% of profit) · FY2024: $1.69 (118.4% of profit) · FY2025: $1.72 (125.7% of profit)
  • Buybacks
    • Dec 31, 2022: Bought $2.0 billion of its own shares in Q1 2022, its last buyback. $3.3 billion of authorization remained on Nov 3, 2026, and Pfizer's 2026 guidance assumes no buybacks. ($2.0B)
  • AuditorKPMG LLP
  • Credit ratingMoody's and S&P, as stated in Pfizer's 10-Q: A2 and A, outlook Stable (Nov 3, 2026)

Sources: Bristol Myers Squibb S3, S1, S14, S5 · Pfizer S3, S1, S4, S12, S6

Risks only one page tracks

Risks whose type the other company's page does not list. Both pages track risks of these types: customer or supplier concentration, pricing, competition, execution, debt. Every risk is on each company's page.

Bristol Myers Squibb

  • Cash collections fell in 2026 (liquidity)Operating cash flow was $8.7 billion in the first nine months of 2026, down $3.5 billion. BMS cites lower net customer receipts from generic erosion and the Eliquis list price cut.

Pfizer

  • COVID-19 revenue has fallen (demand)Comirnaty and Paxlovid fell from 56.1% of revenue in FY2022 to 10.8% in FY2025. They were $2.0 billion in the first nine months of 2026, against $4.2 billion a year earlier.
  • Product liability lawsuits (legal cases)Plaintiffs allege harm from products including Zantac and Depo-Provera. Certain legal matters cost $1.0 billion in the first nine months of 2026, against $755 million a year earlier. Pfizer says it cannot estimate the range of further loss.

Sources: Bristol Myers Squibb S5 · Pfizer S1, S6, S13

Key facts

How does Bristol Myers Squibb make money compared with Pfizer?
Bristol Myers Squibb's revenue by segment in FY2025: Growth Portfolio 54.8%, Legacy Portfolio 45.2%. Pfizer's revenue by segment in FY2025: Primary Care 42.9%, Specialty Care 28.0%, Oncology 26.9%, Other business activities 2.2%.
Which is bigger by revenue, Bristol Myers Squibb or Pfizer?
Bristol Myers Squibb reported $48.2B of revenue in FY2025, and Pfizer reported $62.6B in FY2025.
How much net income did Bristol Myers Squibb and Pfizer report?
Bristol Myers Squibb reported net income of $7.1B in FY2025, and Pfizer reported $7.8B in FY2025.
How much of every $100 did Bristol Myers Squibb and Pfizer keep as net income?
Bristol Myers Squibb kept $14.6 of every $100 that came in during FY2025, and Pfizer kept $12.4 in FY2025 (Cityfort calculation from each company's annual report).
How much debt and cash do Bristol Myers Squibb and Pfizer have?
Bristol Myers Squibb had $42.9B of debt and $13.0B of cash and investments on Sep 30, 2026. Pfizer had $62.7B of debt and $14.3B of cash and investments on Sep 27, 2026.
When do Bristol Myers Squibb's and Pfizer's fiscal years end?
Bristol Myers Squibb: December 31. Pfizer: December 31 for US subsidiaries and November 30 for those abroad, so Q3 FY2026 ended Sep 27, 2026 in the US and Aug 23, 2026 abroad.

Sources: Bristol Myers Squibb S3, S4, S1, S2, S5, S8 · Pfizer S3, S2, S1, S6, S9, S4

Built from each company's page. Bristol Myers Squibb updated Nov 6, 2026; Pfizer updated Nov 6, 2026.

Sources

Bristol Myers Squibb

  1. S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), Bristol-Myers Squibb Company (SEC EDGAR), Feb 11, 2026
  2. S2Form 10-K for fiscal year 2024, Bristol-Myers Squibb Company (SEC EDGAR), Feb 12, 2025
  3. S3Form 10-K for fiscal year 2023, Bristol-Myers Squibb Company (SEC EDGAR), Feb 13, 2024
  4. S4Form 10-K for fiscal year 2022, Bristol-Myers Squibb Company (SEC EDGAR), Feb 14, 2023
  5. S5Form 10-Q for Q3 FY2026 (ended Sep 30, 2026), Bristol-Myers Squibb Company (SEC EDGAR), Oct 29, 2026
  6. S6Form 10-Q for Q2 FY2026 (ended Jun 30, 2026), Bristol-Myers Squibb Company (SEC EDGAR), Jul 30, 2026
  7. S7Form 10-Q for Q1 FY2026 (ended Mar 31, 2026), Bristol-Myers Squibb Company (SEC EDGAR), Apr 30, 2026
  8. S8Form 10-Q for Q3 FY2025 (ended Sep 30, 2025), Bristol-Myers Squibb Company (SEC EDGAR), Oct 30, 2025
  9. S11Earnings release, Q3 FY2026 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Oct 29, 2026
  10. S12Earnings release, Q2 FY2026 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Jul 30, 2026
  11. S13Earnings release, Q1 FY2026 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Apr 30, 2026
  12. S14Earnings release, Q4 FY2025 and full year 2025 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Feb 5, 2026
  13. S15Earnings release, Q3 FY2025 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Oct 30, 2025
  14. S19Proxy statement (DEF 14A) for the 2026 annual meeting, Bristol-Myers Squibb Company (SEC EDGAR), Mar 25, 2026
  15. S20Schedule 13G, State Street Corporation, event Jun 30, 2026, State Street Corporation (SEC EDGAR), Aug 7, 2026
  16. S21Schedule 13G, Vanguard Capital Management, event Mar 31, 2026, Vanguard Capital Management (SEC EDGAR), Apr 29, 2026
  17. S23Schedule 13G/A, BlackRock, Inc., as of Mar 31, 2025, BlackRock, Inc. (SEC EDGAR), Apr 17, 2025

Pfizer

  1. S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), Pfizer Inc. (SEC EDGAR), Feb 26, 2026
  2. S2Form 10-K for fiscal year 2024, Pfizer Inc. (SEC EDGAR), Feb 27, 2025
  3. S3Form 10-K for fiscal year 2023, Pfizer Inc. (SEC EDGAR), Feb 22, 2024
  4. S4Form 10-K for fiscal year 2022, Pfizer Inc. (SEC EDGAR), Feb 23, 2023
  5. S6Form 10-Q for Q3 FY2026 (ended Sep 27, 2026), Pfizer Inc. (SEC EDGAR), Nov 3, 2026
  6. S7Form 10-Q for Q2 FY2026 (ended Jun 28, 2026), Pfizer Inc. (SEC EDGAR), Aug 4, 2026
  7. S8Form 10-Q for Q1 FY2026 (ended Mar 29, 2026), Pfizer Inc. (SEC EDGAR), May 5, 2026
  8. S9Form 10-Q for Q3 FY2025 (ended Sep 28, 2025), Pfizer Inc. (SEC EDGAR), Nov 4, 2025
  9. S12Earnings release for Q3 FY2026 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), Nov 3, 2026
  10. S13Earnings release for Q2 FY2026 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), Aug 4, 2026
  11. S14Earnings release for Q1 FY2026 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), May 5, 2026
  12. S15Earnings release for Q4 FY2025 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), Feb 3, 2026
  13. S16Earnings release for Q3 FY2025 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), Nov 4, 2025
  14. S202026 proxy statement (DEF 14A), Pfizer Inc. (SEC EDGAR), Mar 12, 2026
  15. S21Schedule 13G, Vanguard Capital Management (event Mar 31, 2026), Vanguard Capital Management (SEC EDGAR), May 1, 2026
  16. S278-K filed Nov 13, 2025: Metsera acquisition completed (Item 8.01), Pfizer Inc. (SEC EDGAR), Nov 13, 2025
  17. S32Moderna Form 10-K for fiscal 2025 (year ended December 31, 2025), Moderna, Inc. (SEC EDGAR), Feb 20, 2026

Disclaimer

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.

Read the positions policy
Read the full disclaimer

Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.

All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.